For Immediate Release

Chicago, IL – April 21, 2010 – announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Human Genome Sciences Inc. (HGSI), Novartis AG (NVS), Merck (MRK), Roche (RHHBY) and GlaxoSmithKline plc (GSK).

Get the most recent insight from Zacks Equity Research with the free Profit from the Pros newsletter:

Here are highlights from Tuesday’s Analyst Blog:

Setback for Human Genome Pipeline

Recently, Human Genome Sciences Inc. (HGSI) received a setback when the Marketing Authorization Application (MAA) for its hepatitis C candidate Joulferon (albinterferon alfa-2b) was withdrawn by its partner Novartis AG (NVS).

Novartis, with whom Human Genome entered into an exclusive global agreement for the development and commercialization of the drug in 2006, submitted the MAA to the European Medicines Agency (EMEA) for its hepatitis C candidate in December 2009.

Human Genome and Novartis have selected “Zalbin” as the brand name for albinterferon alfa- 2b in the United States while “Joulferon” is the brand name for the rest of the world.

The drug is under review in the United States. Human Genome submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) in November 2009. The company expects the FDA to approve the drug in the fourth quarter of 2010 (target date: October 4, 2010)

The withdrawal of the MAA was based on indications that the European regulatory authorities would ask for additional data, which the companies may be not be able to furnish in the time frame permissible under the European Centralized Procedure.

The feedback from the European regulatory authorities queried whether the therapeutic benefit offered by Joulferon, dosed once every fortnight, outweighed the risks associated with the candidate.

Joulferon is a novel long-acting form of interferon alpha. Recombinant interferon alpha is approved for the treatment of hepatitis C, hepatitis B and a broad range of cancers. Human Genome modified interferon alpha to improve its pharmacological properties by using its albumin fusion technology.

On approval, we believe that the drug will face tough competition from Merck’s (MRK) PEG-Intron and Roche’s (RHHBY) Pegasys in the interferon alpha market.

We believe that the most eagerly awaited candidate in Human Genome’s pipeline is the lupus candidate Benlysta, co-developed with GlaxoSmithKline plc (GSK), which has blockbuster potential. The company intends to seek approval for Benlysta during the second quarter of 2010 in the United States and Europe. Management expects the drug to be approved in the U.S. in the fourth quarter of 2010.

Want more from Zacks Equity Research? Subscribe to the free Profit from the Pros newsletter:

About Zacks Equity Research

Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.

Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.

Zacks “Profit from the Pros” e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today:

About Zacks is a property of Zacks Investment Research, Inc., which was formed in 1978 by Leonard Zacks. As a PhD in mathematics Len knew he could find patterns in stock market data that would lead to superior investment results. Amongst his many accomplishments was the formation of his proprietary stock picking system; the Zacks Rank, which continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it’s your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros at

Visit for information about the performance numbers displayed in this press release.

Follow us on Twitter:

Join us on Facebook:

Disclaimer: Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.

Mark Vickery
Web Content Editor



Zacks Investment Research